Drug induced hepatotoxicity: A comprehensive review

Internet Journal of Pharmacology

Volumn 7, Issue 1, 2009, Pages

  Kshirsagar, Ajay ^a   Vetal, Yogesh ^b   Ashok, Purnima ^b   Bhosle, Pradnya ^b   Ingawale, Deepa ^b  

^a Karnatak Lingayat Education Society   (India)

^b AISSM'S College of Pharmacy

Author keywords

Drug; Hepatotoxicity; Liver

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BILIRUBIN; EZETIMIBE; HALOTHANE; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; STAVUDINE;

CHRONIC ACTIVE HEPATITIS; CLINICAL FEATURE; CYTOTOXICITY; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; FATTY LIVER; HISTOPATHOLOGY; HUMAN; LIPIDOSIS; LIVER CIRRHOSIS; LIVER NECROSIS; LIVER TOXICITY; LIVER TUMOR; PROTEIN TRANSPORT; REVIEW; VASCULAR LESION;

EID: 77953365616     PISSN: None     EISSN: 15312976     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Davis M, Williams R. Hepatic Disorders. In: Davies DM, editor. Textbook of Adverse Drug Reactions, Oxford: Oxford University Press. 1977. pp 146-172. (s)
2. Zimmerman HJ. Hepatotoxicity, New York: Appleton Century Crofts.1978. (s)
3. Ostapowicz G, Fontana RJ, Schiødt FV. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002; 137(12):947-954. (s)
4. Lee WM. Acute liver failure in the United States. Semin Liver Dis. 2003; 23:217-226. (s)
5. Prescott LF. Hepatotoxicity of mild analgesics. Br J Clin Pharmac. 1980; 10:373-379. (s)
6. Zimmerman HJ. Drug Hepatotoxicity: Spectrum of clinical lesions. In: Davis M, Tredger JM, Williams R, editors. Drug Reactions and the Liver. London: Pitman Medical. 1981. pp 35-53. (s)
7. Capelle P, Dhumeaux D, Mora M, Feldman G, Berthelot P. Effect of rifampicin on liver function in man. Gut. 1972; 13:366-371. (s)
8. Timbrell JA. Drug hepatotoxicity. Br J Clin Pharmac. 1983; 15:3-14. (s)
9. Zimmerman H. Hepatic injury caused by therapeutic agents. In: Becker FF, editor. The Liver. New York: Marcel Dekker. 1974. pp 225-302. (s)
10. Lullman H, Lullman-Rauch R, Wassermann O. Drug induced phospholipidosis. CRC Crit Rev Tox. 1975; 4:185-218. (s)
11. Neuberger JM, Davis M, Williams R. Clinical aspects of oral contraceptive associated liver tumours. In: Davis M, Tredger JM, Williams R, editors. Drug Reactions and the Liver. London: Pitman Medical. 1981. pp 271-283. (s)
12. Wallace JL. Acetaminophen hepatotoxicity: Nitric Oxide to the rescue. Brit J Pharmac. 2004; 143:1-2. (s)
13. Available at http://en.wikipedia.org/wiki/Acetaminophen (s)
14. Available at www.nam.fi/english/news/ press releases/nimed.html (s)
15. Traversa G, Bianchi C, Cas R, Abraha I, Venegoni M. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ. 2003; 327:18-22. (s)
16. Available at http://en.wikipedia.org/wiki/Nimesulide (s)
17. Available at http://en.wikipedia.org/wiki/Aspirin (s)
18. Neuberger J, Kenna JG, Nouri aria K, Williams R. Antibody mediated hepatocyte injury in methyl dopa induced hepatotoxicity. Gut. 1985; 26:1233-1239. (s)
19. Available at http://en.wikipedia.org/wiki/Methyldopa (s)
20. Ali J. Hepatotoxic effects of tuberculosis therapy: A practical approach to a tricky management problem. Postgrad Med. 1996; 99:217-236. (s)
21. Getnet Y, Getachew A, Wondwossen A, Eyasu M, Eleni A, Lars L. Anti-Tuberculosis Therapy-Induced Hepatotoxicity among Ethiopian HIV Positive and Negative Patients. plos one. 2008;3(3):1-5. (s)
22. Available at http://en.wikipedia.org/wiki/Isoniazid (s)
23. Available at http://en.wikipedia.org/wiki/Rifampicin (s)
24. Trowell J, Peto R, Smith AC. Controlled trial of repeated halothane anaesthetics in patients with carcinoma of the uterine cervix treated with radium. Lancet. 1975:821-824. (s)
25. Available at http://en.wikipedia.org/wiki/Halothane (s)
26. Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol. 2006; 44:132-139. (s)
27. Giuseppe L, Ilaria I, Silvia C, Giuliana C, Luisa B, Salvatore C. Dideoxynucleoside HIV reverse transcriptase inhibitors and drug-related hepatotoxicity: a case report. J Med Case Rep. 2007; 1(19). (s)
28. Available at http://en.wikipedia.org/wiki/Stavudine (s)
29. Davis JS. Liver damage due to tetracycline and its relationship to pregnancy. In: Meyler L, Peck HM, editors. Drug Induced Diseases. Amsterdam: Excerpta Medica Foundation. 1968. pp 103-110. (s)
30. Dowling HF, Lepper MH. Hepatic reactions to tetracycline. J Am med Ass. 1964; 188:307-309. (s)
31. Available at http://en.wikipedia.org/wiki/Tetracycline (s)
32. Parra JL, Reddy KR. Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis. 2003; 7(2):415-433. (s)
33. Bhardwaj SS, Chalasani N. Lipid Lowering Agents That Cause Drug-Induced Hepatotoxicity. Clin Liver Dis. 2007; 11(3):597-607. (s)
34. Grimbert S, Pessayre D, Degott C, Benhamou JP. Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin. Digestive Dis Sci. 1994; 39(9):2032-2033. (s)
35. Jimenez-Alonso J, Osorio JM, Guierrez-Cabello F, Osa AL, Leon L, Garcia JDM. Atorvastatin induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Arch Int Med. 1999; 159(15):1811-1812. (s)
36. Nakad A, Bataille L, Hamoir V, Sempoux C, Horsman Y. Atorvastatin induced acute hepatitis with absence of cross-toxicity with simvastatin. Lancet. 1999; 353(9166):1763-1764. (s)
37. Castro ML, Hermo JA, Baz A, de Luaces C, Perez R, Clofent J. Acute cholestatic hepatitis after atorvastatin reintroduction. Gastroenterol Hepatol. 2006; 29(1):21-24. (s)
38. Gershovich OE, Lyman AE. Liver function test abnormalities and pruritis in a patient treated with atorvastatin: case report and review of the literature. Pharmacother. 2004; 24(1):150-154. (s)
39. Ricaurte B, Guirguis A, Taylor HC, Zabriskie D. Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity. Annals Pharmacther. 2006; 40(4):753-757. (s)
40. Kanathur N, Mathai MG, Byrd RP Jr, Fields CL, Roy TM. Simvastatindiltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med. 2001; 94(9):339-341. (s)
41. Hartleb M, Rymarczyk G, Januszewski K. Acute cholestatic hepatitis associated with pravastatin. Am J Gastroenterol. 1999; 94(5):1388-1390. (s)
42. Cox RP, Foltz EL, Ratmond S, Drewyer R. Novobiocin jaundice. New Engl J Med. 1959; 261:139-141. (s)
43. Kenright S, Levi AJ. Sites of competition in the selective uptake of rifamycin-SV, flavaspidic acid, bilirubin and bromoshulphalein. Gut. 1974; 15:220-226. (s)
44. Boyd EM, Bereczky GM. Liver necrosis from paracetamol. Br J Pharmac. 1966; 26:606-614. (s)
45. James O, Roberts SH, Douglas AP. Liver damage after paracetamol overdose. Comparison of liver function tests, fasting serum bile acids and liver histology. Lancet. 1975; 2:579-581. (s)
46. Mitchell JR, Potrer WZ, Hinson JA, Snodgrass WR, Timbrell JA, Gillette JR. Toxic drug reactions. In: Gillette JR, Mitchell JR, editors. Concepts of Biochemical Pharmacology. New York: Springer-Verlag. 1975. pp 383-419. (s)
47. Mitchell JR, Thorgiersson SS, Potter WR, Jollow DJ, Keiser H. Acetaminophen induced hepatic injury: Protective role of glutathione in man and rationale for therapy. Clin Pharmac Ther. 1974; 16:676-684. (s)
48. Popper H. Cholestasis. Ann Rev Med. 1968; 19:39. (s)
49. Schaffner F. In: McIntyre N, Sherlock S, editors. Therapeutic Agents and the Liver. Oxford Blackwell. 1965. pp 99-113. (s)
50. Breen KJ, Schenker S, Heimberg M. Fatty liver induced by tetracycline in the rat; dose-response relationship and effect of sex. Gastroenterol. 1975; 69:714-723. (s)
51. Breen L, Schenker S, Heimberg M. The effect of tetracycline on the hepatic secretion of triglyceride. Biochem Biophys Acta. 1972; 270:74-80. (s)
52. Mitchell JR, Thorgiersson UP, Black M, Timbrell JA, Snodgrass WR, Potter WZ, Jollow DJ, Keiser H. Increased incidence of isoniazid hepatitis in rapid acetylators: Possible relation to hydrazine metabolites. Clin Pharmac Ther. 1975; 18:70-79. (s)
53. Bahri AK, Chiang CS, Timbrell JA. Acetylhydrazine hepatotoxicity. Tox appl Pharmac. 1981; 60:561-569. (s)
54. Lullmann H, Lullmann-Rauch R. Drug induced lipidosis. In: Bundgaard H, Juul P, Kofod H, editors. Drug Design and Adverse Reactions. Copenhagen: Munksgaard. 1977. pp 29-34. (s)
55. Goldfarb S. Sex hormones and hepatic neoplasia. Cancer Res. 1976; 36:2584-2588. (s)
56. Rao RR. Mechanism of drug induced hepatotoxicity. Ind J Pharmac. 1973; 5(2):313-318. (s)
57. McClain CJ, Price S, Barve S, Devalarja R, Shedofsky S. Acetaminophen hepatotoxicity: an update. Curr Gastroenterol Rep. 1999; 1:42-49. (s)
58. Schaller JG. Chronic salicylate administration in juvenile rheumatoid arthritis: aspirin "hepatitis" and its clinical significance. Pediatr. 1978; 62:916-925. (s)
59. Available at http://en.wikipedia.org/wiki/Gabapentin (s)
60. Cheuk-ming T. Monitoring for hepatotoxicity during antituberculosis treatment. 2002. (s)
61. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med. 2002; 166:916-919. (s)
62. Huang YS, Chern HD, Su WJ, Wu JC, Chang SC. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatol. 2003; 37:924-930. (s)
63. Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med. 1998; 157:1871-1876. (s)
64. Bruchfeld J, Bruchfeld J, Aderaye G, Palme IB, Bjorvatn B, Kallenius G. Sputum concentration improves diagnosis of tuberculosis in a setting with a high prevalence of HIV. Trans R Soc Trop Med Hyg. 2000; 94:677-680. (s)
65. Campos-Franco JA, Gonzalez-Quintela, Alende-Sixto MR. Isoniazid induced hyperacute liver failure in a young patient receiving carbamazepine. Eur J Intern Med. 2004; 15:396-397. (s)
66. Barnes PF, Barrows SA. Tuberculosis in the 1990s. Ann Intern Med. 1993; 119: 400-410. (s)
67. Kimmoun E, Samuel D. Antituberculous drugs in patients with chronic liver disease. J Gastroenterol Hepatol. 2002; 17:408-412. (s)
68. Jaime R, Ungo, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, Pitchenik AE. Antituberculosis drug induced hepatotoxicity. Am J Respir Crit Care Med. 1998; 157(6):1871-1876. (s)
69. Stolk MF, Becx MC, Kuypers KC, Seldenrijk CA. Severe hepatic side effects of ezetimibe. Clin Gastroenterol Hepatol. 2006; 4(7):908-911. (s)
70. Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipidlowering agents, psychotropic drugs. Sem Liver Dis. 2002; 22(2):169-183. (s)
71. Jacobson TA. Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol. 2006; 97:44-51. (s)
72. Horsmans Y, Desager JP, Harvengt C. Biochemical changes and morphological alterations of the liver in guinea-pigs after administration of simvastatin (HMG CoA reductase-inhibitor). Pharmacol Toxicol. 1990; 67 (4):336-339. (s)
73. MacDonald JS, Gerson RJ, Kornbrust DJ, Kloss MW, Prahalada S, Berry PH. Preclinical evaluation of lovastatin. Am J Cardiol. 1998; 62(15):16-27. (s)
74. Vogt A, Kassner U, Hostalek U, Steinhagen-Thiessen E. Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting. Curr Med Res Opi. 2006; 22(2):417-425. (s)
75. Dalton TA, Berry RS. Hepatotoxicity associated with sustained-release niacin. Am J Med.1992; 93(1):102-104. (s)
76. Etchason JA, Miller TD, Squires RW, Allison TG, Gau GT, Marttila JK. Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin. Mayo Clin Proceed. 1991; 66(1):23-28. (s)
77. Henkin Y, Johnson KC, Segrest JP. Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin. Jama. 1990; 264 (2):241-243. (s)
78. Hodis HN. Acute hepatic failure associated with the use of low-dose sustained-release niacin. Jama. 1990; 264(2):181. (s)
79. Reimund E, Ramos A. Niacin-induced hepatitis and thrombocytopenia after 10 years of niacin use. J Clin Gastroenterol. 1994; 18(3):270-271. (s)
80. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulat. 2005; 111(18):2356-2363. (s)
81. Nickerson M, Ruedy J. Antihypertensive agents and the drug therapy of hypertension. In: Goodman LS, Gilman AG, Koelle GB, editors. The pharmacological basis of therapeutics. 5th ed. Macmillan: New York. 1975. pp 1350-1368. (s)
82. Rodman JS, Deutsch DJ, Gutman SI. Methyl dopa hepatitis. A report of six cases and a review of the literature. Am J Med. 1976; 60:941-948. (s)
83. Cacace LG, Cohen M. Alpha methyl dopa (Aldomet) hepatitis: Review of a case and review of the literature. Drug Intell Clin Pharmacol. 1976; 10:144-162. (s)
84. Leonard SW, Goffard RW, Humphrey DC. Treatment of hypertension with methyl dopa alone or combined with Guanethedine: A report of 63 cases. Am Heart J. 1965; 69:610- 618. (s)
85. Dybing E. Activation of methyl dopa, paracetamol and frusemide by human liver microsomes. Acta Pharmacol Toxicol. 1977; 41:89-93. (s)
86. Dybing E, Nelson SD, Mitchell JR, Sasame HA, Gilette JR. Oxidation of methyl dopa and other catechols by cytochrome P450 generates superoxide. Possible mechanism of methyl dopa hepatitis. Mol Pharmacol. 1976; 12:911-920. (s)
87. Vergani D, Mieli-Vergani G, Alberti A. Demonstration of a circulating antibody reacting with the surface membrane of halothane-altered hepatocytes in patients with fuiminant hepatitis following halothane anaesthesia. N Engl J Med. 1980; 303:66-71. (s)
88. Tredger JM, Davis M. Drug metabolism and hepatotoxicity Gut. 1991; 34-39. (s)
89. Kenna JG, Neuberger J, Williams R. An enzyme-linked immunosorbent assay for detection of antibodies against halothane-altered hepatocyte antigens. J Immunol Meth. 1984; 75:3-14. (s)
90. Neuberger JM, Davis M. Advances in understanding of halothane hepatitis. Trends Pharm Sci. 1983; 4:19-20. (s)
91. Brown BR, Sipes IG. Biotransformation and hepatotoxicity of halothane. Biochem Pharmacol.1977; 26:2091-2094. (s)
92. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. Jama. 2000; 283:74-80. (s)